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ABSTRACT
Capecitabine, an oral prodrug of 5-fluorouracil (5fu), 
has been integrated into the management of multiple 
cancer types because of convenience of administra-
tion and efficacy comparable with 5fu. Cardiotoxic-
ity induced by 5fu—in particular angina—has been 
well described in the literature, but reports of adverse 
cardiac events with capecitabine are also emerging. 
The mechanism underlying 5fu cardiotoxicity has 
long been thought to result from coronary vasospasm, 
but animal-model studies and patient echocardio-
graphic findings both suggest a cardiomyopathic 
picture. Although 5fu cardiotoxicity is often revers-
ible and can be managed supportively, presentations 
that are more severe—including arrhythmias, acute 
ischemic events, and cardiogenic shock—have been 
documented. In this report, we describe the case of 
a patient who ultimately required a pacemaker after 
developing symptomatic bradycardia and sinus arrest 
while receiving capecitabine for colon cancer.
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1.  CASE DESCRIPTION
A 75-year-old man with known hypertension, diabetes, 
and dyslipidemia was diagnosed with a stage iiib recto-
sigmoid adenocarcinoma in July 2007. He underwent 
a lower anterior resection, and 12 cycles of modified 
folfox-6 [oxaliplatin 85 mg/m2, 5-fluorouracil (5fu) 
400 mg/m2 bolus, and leucovorin (lv) 400 mg/m2, fol-
lowed by 5fu 2.4 g/m2 by continuous infusion over 46 
hours] adjuvant chemotherapy were planned.
Following chemotherapy cycle 7 in late January 
2008, the patient developed atrial fibrillation, and he 
was admitted to the coronary care unit (ccu) at the 
Montreal General Hospital. At that time, echocar-
diography revealed an ejection fraction of 55%–60%, 
mild left ventricular diastolic dysfunction, and mild 
mitral regurgitation, with otherwise normal readings. 
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He was converted to sinus rhythm on oral sotalol 
(80 mg twice daily), with the plan to initiate antico-
agulation upon completion of chemotherapy. One 
week post discharge, he developed an upper extremity 
deep venous thrombosis on the side of his implanted 
catheter, and he was started on dalteparin. Two weeks 
later, his chemotherapy was changed to capecitabine 
monotherapy at 1500 mg/m2 twice daily.
About 6 days after starting capecitabine, the 
patient had a syncopal episode lasting approximately 
2 minutes. He recovered spontaneously and, after 
some transient disorientation, returned to his baseline 
mental status. A few hours later, he experienced two 
presyncopal episodes accompanied by flushing and 
dizziness. He went to the emergency department, 
where he was found to have bradycardia at 54 bpm, 
although he was hemodynamically stable with a 
blood pressure of 140/79 mmHg. Initial blood work 
did not reveal any electrolyte abnormalities or tro-
pinemia. An electrocardiogram demonstrated sinus 
bradycardia (Figure 1).
While on telemetry, the patient had a witnessed 
episode of presyncope associated with a pulse of 
30–40 bpm and systolic pressure between 160–
170 mmHg. With the exception of sotalol, he received 
the evening doses of all of his other medications 
(capecitabine, metformin, venlafaxine, and valsartan) 
and was kept in the emergency department overnight 
for monitoring. Approximately 6 hours later, he had 
a sinus arrest of 15 s, from which he spontaneously 
recovered (Figure 2). Transcutaneous pacemaker 
pads were placed, and he was transferred to the ccu 
with atropine at the bedside. All medications were 
subsequently held.
The rest of the night was uneventful, but the fol-
lowing morning he had recurrent episodes of symp-
tomatic bradycardia followed by another sinus arrest 
lasting 10 s. A transvenous pacemaker was inserted 
followed by a permanent pacemaker a few days later. 
Sotalol was resumed, and he was discharged without 
any further complications. He remains in clinical 
remission from his malignancy, and no further che-
motherapy is planned.
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figure 1  Electrocardiogram taken upon initial presentation of the patient to the emergency department.
figure 2  Electrocardiogram showing development of sinus bradycardia followed by sinus arrest 6 hours after the patient took 
capecitabine.
2.  DISCUSSION
Coronary vasospasm resulting in angina and even 
myocardial infarction is a well-known adverse ef-
fect of 5fu. Although cardiotoxicity is often revers-
ible with discontinuation of 5fu and application of 
supportive care 1, the condition has the potential 
to be fatal. Reported overall mortality rates range 
from 2.2% to as high as 13.3% 2. The incidence of 
5fu-induced cardiotoxicity in the literature ranges 
from 1.2% to 18%, although its true incidence may 
actually be higher, given that silent, reversible ST 61
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segment deviations on electrocardiography are 
known to occur 3,4. Other manifestations of 5fu-
induced cardiotoxicity include heart failure, hyper- or 
hypotension, cardiomyopathy, arrhythmias, conduc-
tion disturbances, and cardiac arrest 5. However, these 
latter cardiac adverse events have been reported 
much less frequently.
Capecitabine is an oral prodrug that is converted 
to 5fu in a sequential 3-step enzymatic reaction that 
occurs primarily in the liver and in tumour cells. It 
has gained popularity because of its efficacy, ease of 
administration, and milder toxicity profile as com-
pared with 5fu 6. However, as the use of capecitabine 
becomes more widespread, the rare but significant 
cardiotoxic potential of the drug is beginning to 
surface. In a retrospective analysis performed on 
studies of patients undergoing chemotherapy for 
metastatic breast and colon cancer, the incidence 
of cardiotoxicity with capecitabine was found to be 
comparable to that of 5fu–lv 7. Wijesinghe et al. 8 
reported an acute coronary syndrome in a patient 
with no history of cardiovascular disease who had 
been on capecitabine for only 2 days. Kosmas et al. 5 
documented myocardial infarction, electrocardio-
graphic abnormalities, and ventricular extrasystoles 
in patients on capecitabine. Furthermore, Goldsmith 
et al. 9 recently reported exercise-induced global myo-
cardial ischemia with an ejection fraction of 36% in 
a patient with normal coronary arteries and resting 
left ventricular function who was on capecitabine for 
recurrent breast cancer.
We present the first reported case of a patient who 
ultimately required a permanent pacemaker after de-
veloping symptomatic bradycardia followed by sinus 
arrest while on capecitabine. Although the patient was 
taking sotalol, which can itself cause bradycardia and 
asystole, the sotalol had been started a month before 
the relevant episode, during which time the patient 
did not experience any of the noted complications. 
Given that capecitabine was started less than a week 
before presentation, it would appear to be the most 
likely culprit in the absence of other medication 
changes at the time.
The clinical manifestations of 5fu cardiotoxic-
ity are frequently attributed to coronary vasospasm. 
However, anti-vasospastic agents including nitro-
glycerin and calcium channel blockers have not 
been consistently effective at relieving symptoms 
of angina in affected patients 1,5,10. In a study by 
Freeman et al. 11, ergonovine challenge followed by 
5fu infusion did not produce coronary vasospasm in 
a patient who had developed severe chest pain and 
ischemic electrocardiographic changes. In vivo stud-
ies in animal models have also provided evidence 
suggesting that mechanisms aside from coronary 
vasospasm may be responsible. Tsibiribi et al. 12 
subjected rabbits to either bolus or infusional 5fu. 
Rabbits that received the bolus suffered massive 
hemorrhagic myocardial infarcts with evidence 
of proximal coronary vasospasm. In contrast, ani-
mals in the infusion group demonstrated histologic 
changes consistent with toxic myocarditis. In addi-
tion, echocardiographic studies in patients with 5fu 
cardiotoxicity have revealed decreased ejection frac-
tion and significant global or regional left ventricu-
lar dysfunction consistent with a cardiomyopathic 
picture 13,14.
The metabolites of 5fu have been implicated in 
mediating cardiac damage, in particular fluoroacetate 
(fac), which is known to be directly myocardiotox-
ic 15. Fluoroacetate is converted into an inhibitor of 
citrate metabolism 16 and interestingly, intramyocar-
dial citrate accumulation has been found in guinea pig 
recipients of 5fu 17. A report by de Forni et al. 18 also 
noted a trend toward increased urinary excretion of 
fac during 5fu administration in 14 patients, including 
6 who developed cardiotoxicity, although there was 
no strict temporal relationship with symptom onset. 
Other hypothesized mechanisms that are undergo-
ing further investigation include the possibility of 
an autoimmune reaction, endothelial damage, and a 
procoagulable effect of 5fu 19,20.
The route of administration, the dose intensity, 
and the schedule of 5fu also appear to influence the 
development of cardiotoxicity. In studies by Jensen et 
al. 2 and Kosmas et al. 5, a higher frequency of symp-
toms was recorded with continuous 5fu infusions 
(24 hours) than with shorter (<3 hours) infusions. 
Given that the pharmacokinetics of capecitabine 
mimic a continuous 5fu infusion, it is not surpris-
ing that the frequency of cardiac symptoms noted 
with capecitabine is similar to that with the 24-hour 
infusion 5. Higher doses of 5fu were associated with 
earlier symptom onset, and a weak trend toward 
longer symptom duration with capecitabine than with 
intravenous 5fu was also observed 2.
Drug pharmacokinetics and pharmacodynamics 
should also be considered to be additional factors that 
may predispose patients to developing cardiotoxicity 
with capecitabine. Lethal gastrointestinal toxicities 
have been reported with capecitabine, which have 
been attributed to a deficiency of dihydropyridine 
dehydrogenase (dpd), the first enzymatic step in 5fu 
catabolism 21. Cytidine deaminase (cda) is a critical 
enzyme for the activation of capecitabine in hepato-
cytes and tumour cells. Excessive levels of cda result-
ing in overmetabolism of capecitabine into 5fu could 
explain the development of severe toxicities even in 
patients who are not dpd-deficient 22. Interestingly, 
geographic differences in tolerance to capecitabine 
have been documented, with the highest rates of toxic-
ity occurring in American patients and the lowest in 
East Asian patients 23. Although cultural and dietary 
differences, in addition to regional variations in the 
reporting of toxicities, may have contributed to these 
observations, polymorphisms in the genes responsible 
for 5fu and capecitabine metabolism may have been 
a factor as well 23.
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The patient presented here received capecitabine 
after experiencing a cardiac event (atrial fibrilla-
tion) while on 5fu. It is unclear whether his atrial 
fibrillation was a result of exposure to 5fu. Although 
the patient had risk factors for coronary artery disease, 
he never exhibited clinical, electrocardiographic, or 
laboratory abnormalities to suggest that ischemia 
contributed to his conduction abnormalities. Nev-
ertheless, this case raises several important issues, 
the first of which is how one might identify patients 
who may be at risk of developing cardiotoxicity on 
5fu. In some studies, a history of heart disease was 
a risk factor for experiencing a higher incidence and 
grade of cardiotoxicity 2,24,25. Conversely, Tsibiribi 
et al. reported symptoms of cardiotoxicity in 16 
patients with no prior cardiac history 26. Other risk 
factors include advanced age, renal insufficiency 2, 
and mediastinal irradiation (which induces coronary 
artery intraluminal hyperplasia and collagen depo-
sition 27). In view of what is being learned about 
the pharmacokinetics of capecitabine and 5fu, the 
measurement of key enzymes such as dpd and cda 
might eventually become important in helping to 
predict—and hopefully spare patients from—severe 
toxicities resulting from these drugs.
Another issue relates to monitoring while on 
therapy, with the goal of detecting preclinical mark-
ers of toxicity. Holubec et al. 28 recently evaluated the 
utility of measuring brain natriuretic peptide (bnp) 
and troponin I (tni) in patients receiving 5fu-based 
chemotherapy for colorectal cancer. In that study, 57% 
of patients were found to have laboratory evidence of 
ischemia and heart failure. Upon questioning, patients 
recalled transient symptoms of angina, dyspnea, and 
edema, although the timing of biomarker eleva-
tion and symptom onset was not precisely defined. 
Given the high incidence of cardiotoxicity that was 
observed, the authors proposed that all patients for 
whom 5fu chemotherapy is planned should undergo 
baseline electrocardiographic screening or, in those 
with prior cardiac history, echocardiography. They 
also suggested that tni and bnp be monitored through-
out the course of chemotherapy as surrogate markers 
of cardiotoxicity.
Finally, there is the question of rechallenging 
and giving prophylaxis to patients who have expe-
rienced cardiotoxicity but who nevertheless stand 
to benefit from 5fu. Cianci et al. 29 successfully 
re-administered 5fu to 3 patients who developed 
symptoms of angina during the initial infusion—
albeit using reduced doses administered together 
with prophylactic trans-epidermal nitroglycerin. 
In another case series of 6 patients who developed 
transient asymptomatic bradycardia on infusional 
5fu, 4 patients were able to continue treatment, 
but 2 had to change their regimen because of per-
sistent and recurring bradycardia with subsequent 
cycles 30. Patients in series reporting more severe 
cardiotoxicity, such as myocardial infarction, were 
not rechallenged 7,31. In such patients, for whom a 
rechallenge of 5fu or capecitabine seems too risky, 
raltitrexed appears to be a viable substitute 25.
3.  CONCLUSIONS
In summary, cardiotoxicity induced by 5fu or 
capecitabine has multiple manifestations and may 
occur more frequently than previously reported. 
Although this cardiotoxicity is transient and often re-
versible, it has the potential to cause serious morbidity 
and even mortality. There are currently no published 
guidelines for screening, monitoring, and prophylaxis. 
Decisions with respect to managing and rechallenging 
patients who have developed cardiotoxicity on 5fu 
must be made on an individual basis. Oncologists 
and cardiologists alike must maintain a heightened 
awareness of the possibility of this phenomenon and 
collaborate closely to ensure patient safety.
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